ArticleDiabetologia2025
Differences in biopsy-proven diabetic kidney disease in individuals from Polynesia vs mainland France: a retrospective cohort study.
Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisMāori, a Polynesian population, have an earlier age of onset of type 2 diabetes and higher risk of diabetes-related complications compared with New Zealanders of European descent, and an increased incident rate ratio for end stage kidney disease. No data are available regarding the evolutive characteristics of diabetic kidney disease (DKD) in individuals living in French Polynesia.
methodsWe aimed to compare the retrospectively collected characteristics and outcomes of 92 and 63 individuals from French Polynesia and mainland France, respectively, presenting type 2 diabetes and biopsy-confirmed DKD, focusing on kidney survival, analysis of the Renal Pathology Society (RPS) score and participant survival.
resultsAt the time of biopsy, Polynesian participants were younger (56.5 vs 66.9 years, p<0.001) and had a higher urinary protein/creatinine ratio (uPCR) (792 vs 452 mg/mmol, p<0.001), despite similar anti-proteinuria treatments and eGFR, and shorter time since diabetes diagnosis (8.7 vs 11.1 years, p=0.008). Polynesian participants had a more severe RPS classification (p<0.001). Median time from biopsy to kidney failure with replacement therapy was 1.59 years in the Polynesian population and 6.06 years in the mainland French population, accounting for death as a competing risk. Polynesian participants were at a higher risk of end stage kidney disease after adjustment for uPCR, eGFR, BMI and age at baseline (HR 2.45 [95% CI 1.23, 4.88]). In a clinical and histological reduced multivariable model, Polynesian origin, higher uPCR, lower eGFR, more severe RPS classification and presence of chronic vascular lesions were all independently associated with poorer kidney survival. The RPS classification was more strongly associated with kidney survival in participants from Polynesia (p value for interaction, 0.048), while a higher uPCR was more strongly associated with kidney survival in participants from mainland France (p value for interaction, <0.001). Older age and Polynesian origin were also independent risk factors for death. CONCLUSIONS/
interpretationStarting at an earlier age, the evolutive course of DKD is also more severe in individuals from French Polynesia than from mainland Western Europe. Strong differences in clinical, histological and predictive outcomes of diabetic nephropathy were found in these different ethnic groups.
Indexed as
Identifiers
40579640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.